PROGRAM CHAIR
Jason J. Luke, MD, FACP
Associate Director for Clinical Research
Director, Immunotherapy and Drug Development Center
Associate Professor of Medicine
UPMC Hillman Cancer Center and University of Pittsburgh
Pittsburgh, PA
PROGRAM OVERVIEW
This enduring activity focusses on the role of immunotherapy for advanced melanoma, its efficacy and safety, as well as strategies to mitigate immunotherapy-associated adverse events. Through case-based learning and expert perspectives, this activity aims to provide clinicians with practical tools and strategies to inform treatment decisions and patient selection for the use of immunotherapy. In addition, this program reviews individualized treatment plans for patients with advanced melanoma.
TARGET AUDIENCE
This activity is intended for US-based community oncologists and other allied healthcare professionals involved in the management of patients with melanoma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the safety and efficacy of immunotherapy for advanced melanoma
- Construct strategies for integrating immunotherapy into individualized patient management plans for advanced melanoma
- Develop evidence-based strategies for mitigating irAEs associated with immunotherapies for patients with advanced melanoma
- Formulate strategies to effectively select patients who would benefit the most from immunotherapy to achieve optimal, long-term outcomes
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Jason J. Luke, MD, FACP | Dr. Luke discloses that he is a consultant for AbbVie, Agenus, Alnylam, AstraZeneca, AskGene Pharma, Atomwise, Bayer, Bristol Myers Squibb, Castle Biosciences, Checkmate Pharmaceuticals, Codiak BioSciences, Crown Pharmaceuticals, Cugene, Curadev, Day One Biopharmaceuticals, Eisai, EMD Serono, Endeavor BioMedicines, Flame Biosciences, G1 Therapeutics, Genentech, Geneos Therapeutics, Gilead Sciences, Glenmark Pharmaceuticals, HotSpot Therapeutics, Kadmon, KoBioLabs, Krystal Biotech, KSQ Therapeutics, Janssen, Ikena Oncology, Inzen, Immatics, Immunocore, Incyte, Instil, IO Biotech, LegoChem Biosciences, Lyvgen Biopharma, MacroGenics, Merck, Mersana Therapeutics, Nektar Therapeutics, Novartis, Partner Therapeutics, Pfizer, Pioneering Medicines, PsiOxus Therapeutics, Regeneron, Replimune, Ribon Therapeutics, Roivant Sciences, Servier, STINGthera, Storm Therapeutics, Sumitomo Dainippon Pharma Oncology, Synlogic, Synthekine, and Teva. He provides research support for AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Corvus Pharmaceuticals, Day One Biopharmaceuticals, EMD Serono, F-star Therapeutics, Genmab, Hot Spot, Ikena, Immatics, Imugene, Incyte, Janux Therapeutics, Kadmon, KAHR Medical, MacroGenics, Merck, Moderna, Nektar, Next Cure, Novartis, Numab Therapeutics, Palleon Pharmaceuticals, Pfizer, Replimune, Rubius Therapeutics, Servier, Scholar Rock, Synlogic, Takeda Pharmaceuticals USA, Trishula, Tizona, Tscan, Werewolf Therapeutics, and Xencor. He is an advisor for 7 Hills Pharma, Affivant Sciences, BioCytics, Bright Peak Therapeutics, Exo Therapeutics, Fstar, Inzen, RefleXion, Xilio (stock) Actym, Alphamab Oncology, Arch Oncology, Duke Street Bio, Elipscience, Kanaph Therapeutics, NeoTx, Onc.AI, OncoNano Medicine, physIQ, Pyxis Oncology, Saros Therapeutics, STipe Therapeutics, and Tempest. He is on the DSMB for AbbVie, Agenus, Evaxion Biotech, Immutep, and Shionogi. He has obtained the patent US-11638728 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof). |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Dominique Barton, B.S. BSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Shpetim Karandrea, PhD Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Program Director for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 20, 2024
EXPIRATION DATE: November 20, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
